Transcatheter Aortic Valve Implantation In A Patient With Systemic Senile Transthyretin Type Amyloidosis
Keywords:
TAVI, CoreValve, atrioventricular block, amyloidosisAbstract
Trancatheter aortic valve implantation with CoreValve or Edwards-Sapien prosthesis is becoming the method of choice for treating severe, symptomatic aortic stenosis in surgical high risk patients. CoreValve implantation may worsen atrioventricular conduction with possible development of atrioventricular block. However, in patients with infiltrative cardiomyopathy, such as amyloidosis, conduction disturbances can be the result of the underlying disease alone.
88-yr old female patient with severe, symptomatic aortic stenosis, after was scheduled for transcatheter aortic valve implantation. The procedure itself was successfully performed however, after the procedure transient complete atrioventricular block developed and a temporary pacemaker electrode was inserted. One day after the procedure the atrioventricular block resolved into her basic heart rhythm which was chronic atrial fibrillation with slow ventricular response. Due to development of systemic signs of infection of unknown origin the temporary electrode was removed and implantation of permanent VVI-type pacemaker was indicated. While waiting for implantation the patient died of sudden cardiac death.
Results of autopsy showed a CoreValve in the proper aortic valve position without blocking the ostia of coronary arteries, mildly enlarged and moderately thickened left and right ventricles on macroscopic level. Histopathological examination showed that the patient had an underlying systemic senile amyloidosis of the transthyretin type with predominant involvement of the heart.
Our patient, who has undergone a transcatheter aortic valve implantation due to severe, symptomatic aortic stenosis, after two balloon valvuloplasties, was also suffering from systemic senile amyloidosis of transthyretin type. This was discovered only postmortem on autopsy.
Transcatheter aortic valve implantation may cause iatrogenic transient or permanent conduction disturbances with possible development of atrioventricular block and present the need for transient or permanent pacemaker implantation. However, her underlying infiltrative cardiomyopathy, could also lead to the same conduction system abnormalities. It is hard to conclude whether conduction disturbances in this case that lead to sudden cardiac death were entirely iatrogenic or entirely due to amyloidosis. In terms of complete atrioventricular block developing just after the procedure and ending in sudden cardiac death, conduction disturbances may have been due to her underlying infiltrative cardiomyopathy and exacerbated by the CoreValve implantation.Â
References
Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation 2002;106:3006-8.
Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, Sinhal A, et al. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007;116:755-763.
Grube E, Shuler G, Buellersfeld L, Gerckens U, Linke A, Wenaweser P, Sauren B, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and third- generation self expanding CoreValve prosthesis: Device success and 30-day clinical outcome. J Am CollCardiol 2007;50:69-76.
Cribier A, Eltchaninof H, Tron C, Bauer F, Agatiello C, Nercolini D, Tapiero S, et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: Mid-term follow-up from the initial feasibility studies: The French experience. J Am CollCardiol 2006;47:1214-23.
Rubin JM, Avanzas P, Del Valle R, Renilla A, RÃos E, Calvo D, Lozano I, et al. Atrioventricular conduction disturbance characterization in transcatheter aortic valve implantation with CoreValve prosthesis. CircCardiovascInterv 2011;Epub ahead of print.
Ferreira ND, Caeiro D, Adao L, Oliveira M, Gonçalves H, Ribeiro J, Teixeira M, et al. Incidence and predictors of permanent pacemaker requirement after transcatheter aortic valve implantation with a self-expanding bioprosthesis. Pacing Clin Electrophysiol. 2010;33(11):1364-72.
Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, et al. Transthyretin-related amyloidosis and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
Baan JJ, Yong Z, Koch K, Henriques JP, Bouma BJ, Vis MM, Cocchieri R, et al. Factors associated with cardiac conduction disorders and permanent pacemaker implantation after percutaneous aortic valve implantation with the CoreValve prosthesis. Am Heart J 2010;159:497-503.
Leon M, Smith C, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-1607.
Koos R, Mahnken AH, Aktug O, Dohmen G, Autschbach R, Marx N, Hoffmann R. Electrocardiographic and imaging predictors for permanent pacemaker requirement after transcatheter aortic valve implantation. J Heart Valve Dis 2011;20(1):83-90.
Rutger-Jan N, Van Mieghem NM, Schultz CJ, Schultz CJ, Tzikas A, Van der Boon RM, Maugenest AM, et al. Timing and potential mechanisms of new conduction abnormalities during implantation of the Medtronic CoreValve System in petients with aortic stenosis. Eur Heart J 2011; Aug;32(16):2067-74.
Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, Anderson RH. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. CirccardiovascInterv 2008;1:74-81.
Godino C, Maisano F, Montorfano M, Latib A, Chieffo A, Michev I, Al-Lamee R et al. Outcomes after transcatheter aortic valve implantation with both Edwards-Sapien and CoreValve devices in a single center: the Milan experience. JACC CardiovascInterv 2010;3:1110-1121.
Bleiziffer S, Ruge H, Horer J, Hutter A, Geisbüsch S, Brockmann G, Mazzitelli D et al. Predictors for new-onset complete heart block after transcatheter aortic valve implantation. JACC CardiovascInterv 2010;1:310-316.
Downloads
Published
Issue
Section
License
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.
